Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.

Tenshin H, Teramachi J, Oda A, Amachi R, Hiasa M, Bat-Erdene A, Watanabe K, Iwasa M, Harada T, Fujii S, Kagawa K, Sogabe K, Nakamura S, Miki H, Kurahashi K, Yoshida S, Aihara K, Endo I, Tanaka E, Matsumoto T, Abe M.

Blood Adv. 2017 Oct 26;1(24):2124-2137. doi: 10.1182/bloodadvances.2017008813. eCollection 2017 Nov 14.

2.

Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway.

Guo J, Fei C, Zhao Y, Zhao S, Zheng Q, Su J, Wu D, Li X, Chang C.

Oncotarget. 2017 Jul 15;8(33):55405-55421. doi: 10.18632/oncotarget.19265. eCollection 2017 Aug 15.

3.

Evolutionary Dynamics of Tumor-Stroma Interactions in Multiple Myeloma.

Sartakhti JS, Manshaei MH, Bateni S, Archetti M.

PLoS One. 2016 Dec 28;11(12):e0168856. doi: 10.1371/journal.pone.0168856. eCollection 2016.

4.

A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration.

Amachi R, Hiasa M, Teramachi J, Harada T, Oda A, Nakamura S, Hanson D, Watanabe K, Fujii S, Miki H, Kagawa K, Iwasa M, Endo I, Kondo T, Yoshida S, Aihara KI, Kurahashi K, Kuroda Y, Horikawa H, Tanaka E, Matsumoto T, Abe M.

Oncotarget. 2016 Oct 25;7(43):70447-70461. doi: 10.18632/oncotarget.11927.

5.

Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.

Blatt K, Herrmann H, Stefanzl G, Sperr WR, Valent P.

Oncotarget. 2016 Oct 4;7(40):65627-65642. doi: 10.18632/oncotarget.11593.

6.

Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.

Bam R, Khan S, Ling W, Randal SS, Li X, Barlogie B, Edmondson R, Yaccoby S.

BMC Cancer. 2015 Nov 6;15:864. doi: 10.1186/s12885-015-1892-7.

7.

Notch signaling deregulation in multiple myeloma: A rational molecular target.

Colombo M, Galletti S, Garavelli S, Platonova N, Paoli A, Basile A, Taiana E, Neri A, Chiaramonte R.

Oncotarget. 2015 Sep 29;6(29):26826-40. doi: 10.18632/oncotarget.5025. Review.

8.

Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease.

Westhrin M, Moen SH, Holien T, Mylin AK, Heickendorff L, Olsen OE, Sundan A, Turesson I, Gimsing P, Waage A, Standal T.

Haematologica. 2015 Dec;100(12):e511-4. doi: 10.3324/haematol.2015.124511. Epub 2015 Aug 20. No abstract available.

9.

Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype.

Beider K, Bitner H, Leiba M, Gutwein O, Koren-Michowitz M, Ostrovsky O, Abraham M, Wald H, Galun E, Peled A, Nagler A.

Oncotarget. 2014 Nov 30;5(22):11283-96.

10.

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.

Garcia-Gomez A, De Las Rivas J, Ocio EM, Díaz-Rodríguez E, Montero JC, Martín M, Blanco JF, Sanchez-Guijo FM, Pandiella A, San Miguel JF, Garayoa M.

Oncotarget. 2014 Sep 30;5(18):8284-305.

11.

Notch signaling drives multiple myeloma induced osteoclastogenesis.

Colombo M, Thümmler K, Mirandola L, Garavelli S, Todoerti K, Apicella L, Lazzari E, Lancellotti M, Platonova N, Akbar M, Chiriva-Internati M, Soutar R, Neri A, Goodyear CS, Chiaramonte R.

Oncotarget. 2014 Nov 15;5(21):10393-406.

12.

Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Garcia-Gomez A, Sanchez-Guijo F, Del Cañizo MC, San Miguel JF, Garayoa M.

World J Stem Cells. 2014 Jul 26;6(3):322-43. doi: 10.4252/wjsc.v6.i3.322. Review.

13.

The role of chemoattractant receptors in shaping the tumor microenvironment.

Zhou J, Xiang Y, Yoshimura T, Chen K, Gong W, Huang J, Zhou Y, Yao X, Bian X, Wang JM.

Biomed Res Int. 2014;2014:751392. doi: 10.1155/2014/751392. Epub 2014 Jul 10. Review.

14.

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.

Bam R, Venkateshaiah SU, Khan S, Ling W, Randal SS, Li X, Zhang Q, van Rhee F, Barlogie B, Epstein J, Yaccoby S.

Blood Cancer J. 2014 Aug 1;4:e234. doi: 10.1038/bcj.2014.54.

15.

On the antiquity of cancer: evidence for metastatic carcinoma in a young man from ancient Nubia (c. 1200 BC).

Binder M, Roberts C, Spencer N, Antoine D, Cartwright C.

PLoS One. 2014 Mar 17;9(3):e90924. doi: 10.1371/journal.pone.0090924. eCollection 2014.

16.

Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway.

Atsuta I, Liu S, Miura Y, Akiyama K, Chen C, An Y, Shi S, Chen FM.

Stem Cell Res Ther. 2013;4(5):111.

17.

Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.

Ramachandran IR, Martner A, Pisklakova A, Condamine T, Chase T, Vogl T, Roth J, Gabrilovich D, Nefedova Y.

J Immunol. 2013 Apr 1;190(7):3815-23. doi: 10.4049/jimmunol.1203373. Epub 2013 Mar 4.

18.

Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.

Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X, van Rhee F, Usmani S, Barlogie B, Shaughnessy J, Epstein J, Yaccoby S.

Am J Hematol. 2013 Jun;88(6):463-71. doi: 10.1002/ajh.23433. Epub 2013 Mar 28.

19.

NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.

Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, Usmani S, Barlogie B, Epstein J, Yaccoby S.

Exp Hematol. 2013 Jun;41(6):547-557.e2. doi: 10.1016/j.exphem.2013.02.008. Epub 2013 Feb 19.

20.

CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.

Dairaghi DJ, Oyajobi BO, Gupta A, McCluskey B, Miao S, Powers JP, Seitz LC, Wang Y, Zeng Y, Zhang P, Schall TJ, Jaen JC.

Blood. 2012 Aug 16;120(7):1449-57. doi: 10.1182/blood-2011-10-384784. Epub 2012 May 22.

Supplemental Content

Support Center